Commit To Buy Infinity Pharmaceuticals At $10, Earn 10% Using Options
at The Street - Wed Dec 24, 11:10AM CST
Investors eyeing a purchase of Infinity Pharmaceuticals Inc shares, but tentative about paying the going market price of $16.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
INFI: 16.65 (+0.37)
Shares of INFI Up 44.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Dec 23, 11:37AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 4 months, Infinity Pharmaceuticals has returned 43.98% as of today's recent price of $16.19.
INFI: 16.65 (+0.37)
Biotech Equities Technical Analysis -- Incyte, ZIOPHARM Oncology, Hemispherx Biopharma, Infinity Pharma, and Orexigen Therapeutics
PR Newswire - Fri Dec 19, 8:15AM CST
Investor-Edge has initiated coverage on the following equities: Incyte Corporation (NASDAQ: INCY), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Hemispherx Biopharma Inc. (NYSE MKT: HEB), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), and Orexigen Therapeutics Inc. (NASDAQ: OREX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 18, 2014, rallied as the Dow Jones Industrial Average finished at 17,778.15, up 2.43% and the NASDAQ Composite closed at 4,748.40, up 2.24%. The S&P 500 finished the session 2.40% higher at 2,061.23. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 813.60, up 2.77%, with the index advancing 8.37% in the previous three months. Register for your complimentary reports on these five stocks at:
OREX: 5.98 (+0.01), ZIOP: 4.76 (+0.07), HEB: 0.22 (-0.02), INCY: 71.57 (+1.99), INFI: 16.65 (+0.37)
Nasdaq stocks posting largest percentage decreases
AP - Tue Dec 16, 5:41PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
NVEE: 12.78 (-0.19), LGCY: 11.86 (-0.49), KNDI: 12.90 (+0.99), EFOI: 5.10 (+0.01), MCEP: 6.07 (-0.12), LMCK: 34.04 (+0.31), SPAN: 17.37 (-0.20), LMCB: 34.76 (+0.86), LMCA: 34.41 (+0.18), LNCO: 10.87 (-0.44), CONN: 18.23 (+1.23), INFI: 16.65 (+0.37), LINE: 10.93 (-0.32), CLMT: 22.15 (-0.08)
Infinity Pharmaceuticals Has Returned 39.0% Since SmarTrend Recommendation (INFI)
Comtex SmarTrend(R) - Tue Dec 16, 9:37AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 4 months, Infinity Pharmaceuticals has returned 39.00% as of today's recent price of $15.63.
INFI: 16.65 (+0.37)
Weakness Seen in Infinity Pharmaceuticals (INFI): Stock Falls 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:30AM CST
Shares of Infinity Pharmaceuticals (INFI) fell over 12% on the day. This reverses the most recent downtrend for INFI, as the stock is up nearly 15% since Nov 19. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
ACRX: 6.61 (+0.06), LCI: 42.29 (+1.79), INFI: 16.65 (+0.37), IG: 9.11 (-0.01)
Allergic Asthma - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/28fk26/allergic_asthma) has announced the addition of the "Allergic Asthma - Pipeline Review, H2 2013" report to their offering. 'Allergic Asthma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergic Asthma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Asthma. Allergic Asthma - Pipeline Review, Half Year is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergic Asthma. - A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergic Asthma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Ablynx NV - Dainippon Sumitomo Pharma Co., Ltd. - Infinity Pharmaceuticals, Inc. - Novartis AG - ALK-Abello A/S - ASKA Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Portola Pharmaceuticals, Inc. - CSL Limited - Stallergenes S.A. - Cytos Biotechnology AG - Panacea Biotec Limited - Marinomed Biotechnologie GmbH - Allergopharma Joachim Ganzer KG - Funxional Therapeutics Ltd - AIM Therapeutics Inc. - Asmacure Ltee - IXO Therapeutics Limited - Protectimmun GmbH - Visionary Pharmaceuticals, Inc. - Trident Pharmaceuticals, Inc. - sterna biologicals Gmbh & Co KG - S-TARget therapeutics GmbH - PanPharmaceuticals USA, Inc. - Peptinnovate Limited For more information visit http://www.researchandmarkets.com/research/28...gic_asthma
PTLA: 28.35 (+0.21), AZN: 70.44 (+0.26), INFI: 16.65 (+0.37), NVS: 93.91 (+0.66)
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/pjf6vv/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - MedImmune, LLC - Infinity Pharmaceuticals, Inc. - Piramal Enterprises Limited - Novartis AG - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Celgene Corporation - Immunomedics, Inc. - TG Therapeutics, Inc. - Pharmacyclics, Inc. - MorphoSys AG - Threshold Pharmaceuticals, Inc. - Onconova Therapeutics, Inc. - LFB S.A. - Advancell - Rhizen Pharmaceuticals SA - AbbVie Inc. - SpectraMab GmbH For more information visit http://www.researchandmarkets.com/research/pjf6vv/refractory
IMMU: 4.41 (+0.13), PCYC: 121.84 (+1.15), TGTX: 16.03 (+0.33), ONTX: 3.82 (+0.06), BMY: 59.15 (-0.01), GSK: 42.85 (+0.11), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86), INFI: 16.65 (+0.37), CELGZ: 3.34 (-0.01), NVS: 93.91 (+0.66)
T-Cell Lymphomas - Pipeline Review, H2 2014
M2 - Thu Dec 11, 3:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/2wvfhz/tcell_lymphomas) has announced the addition of the "T-Cell Lymphomas - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - arGEN-X - Bristol-Myers Squibb - Celgene - Cell Medica - Infinity Pharmaceuticals - Karyopharm Therapeutics - Kyowa Hakko Kirin - Nippon Kayaku - Novartis - Ono Pharmaceutical - Onyx Pharmaceuticals - Pharma Mar - Pharmacyclics - Seattle Genetics - Sigma-Tau For more information visit http://www.researchandmarkets.com/research/2w..._lymphomas
INFI: 16.65 (+0.37), BMY: 59.15 (-0.01), NVS: 93.91 (+0.66), KPTI: 37.78 (+1.28), CELGZ: 3.34 (-0.01)
Infinity Reports New Results from Phase 1 Study of Investigational Oncology Compound Duvelisib at the American Society of Hematology Annual Meeting
Business Wire - Tue Dec 09, 10:30AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported updated data from a Phase 1 monotherapy study of duvelisib (IPI-145), an inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which showed activity among patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), a fatal type of blood cancer. In the study, duvelisib demonstrated an overall response rate of 72 percent, including a 33 percent complete response rate, among 18 patients with iNHL who received the dose administered in ongoing registration-focused studies. In a separate presentation, updated Phase 1 data were also reported showing the activity of duvelisib in patients with relapsed/refractory T-cell lymphoma. These data were presented today at the 56th Annual Meeting of the American Society of Hematology (ASH).
INFI: 16.65 (+0.37)
Infinity Pharmaceuticals Has Returned 40.5% Since SmarTrend Recommendation (INFI)
Comtex SmarTrend(R) - Tue Dec 09, 9:09AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 4 months, Infinity Pharmaceuticals has returned 40.47% as of today's recent price of $15.80.
INFI: 16.65 (+0.37)
Infinity Reports New Translational Research and Updated Phase 1 Data of Investigational Oncology Compound Duvelisib at American Society of Hematology Annual Meeting
Business Wire - Mon Dec 08, 9:45AM CST
--- Updated Phase 1 Data Highlight Duvelisib Activity as a Monotherapy in Relapsed/Refractory Chronic Lymphocytic Leukemia -
INFI: 16.65 (+0.37)
Upgrade Alert for Infinity Pharmaceuticals (INFI)
Comtex SmarTrend(R) - Thu Dec 04, 6:55AM CST
Infinity Pharmaceuticals (NASDAQ:INFI) was upgraded from Neutral to Outperform at Credit Suisse today. The stock closed yesterday at $15.38 on volume of 764,000 shares, above average daily volume of 610,000. Infinity Pharmaceuticals, Inc. researches and develops cancer drugs. The Company uses small molecule drug technologies in the development of its products.
INFI: 16.65 (+0.37)
Shares of INFI Up 32.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 01, 4:43PM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 4 months, Infinity Pharmaceuticals has returned 32.77% as of today's recent price of $14.93.
INFI: 16.65 (+0.37)
Infinity Pharmaceuticals (INFI) Is Today's Strong On High Volume Stock
at The Street - Wed Nov 26, 9:02AM CST
Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate
INFI: 16.65 (+0.37)
Infinity Pharmaceuticals Shares Up 26.3% Since SmarTrend's Buy Recommendation (INFI)
Comtex SmarTrend(R) - Mon Nov 24, 11:10AM CST
SmarTrend identified an Uptrend for Infinity Pharmaceuticals (NASDAQ:INFI) on August 13th, 2014 at $11.25. In approximately 3 months, Infinity Pharmaceuticals has returned 26.32% as of today's recent price of $14.21.
INFI: 16.65 (+0.37)
Post Earnings Update: Infinity Pharmaceuticals Has Climbed 17.1% Higher in Past 2 Weeks (INFI)
Comtex SmarTrend(R) - Mon Nov 24, 8:55AM CST
Two weeks ago on November 6th, 2014 Infinity Pharmaceuticals (NASDAQ:INFI) reported earnings and analysts, on average, expected earnings of $1.26 on sales of $137.5 million. Infinity Pharmaceuticals actually reported earnings of $2.03 per share on sales of $160.6 million, beating EPS estimates by $0.77 and beating revenue estimates by $23.1 million. Since the company's report, shares of Infinity Pharmaceuticals have risen from $12.14 to $14.21, representing a gain of 17.1% in the past 18 days.
INFI: 16.65 (+0.37)
Infinity to Present at the Deutsche Bank Securities 2014 BioFEST Conference
Business Wire - Mon Nov 24, 7:00AM CST
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the Deutsche Bank Securities 2014 BioFEST Conference on December 1, 2014 at 2:15 p.m. ET in Boston.
DB: 30.95 (+0.04), INFI: 16.65 (+0.37)
Infinity Pharmaceuticals Earnings In Retrospect: Up 16.1% in the Last 11 Days (INFI)
Comtex SmarTrend(R) - Mon Nov 17, 1:03PM CST
When Infinity Pharmaceuticals (NASDAQ:INFI) reported earnings 11 days ago on November 6th, 2014, analysts, on average, expected the company to report earnings of $1.26 on sales of $137.5 million. Infinity Pharmaceuticals actually reported earnings of $2.03 per share on sales of $160.6 million, beating EPS estimates by $0.77 and beating revenue estimates by $23.1 million. Since the company's report, shares of Infinity Pharmaceuticals have risen from $12.14 to $14.10, representing a gain of 16.1% in the past 11 days.
INFI: 16.65 (+0.37)